of cash flows, Novartis has been doing quite nicely. With nearly $12 billion of operating cash inflow in fiscal year 2011, Novartis was able to distribute nearly $9 billion of that to shareholders through buybacks and dividends. I predict Vaccines and Diagnostics

companies led by Teva Pharmaceutical Industries Ltd. (TEVA) and Novartis AG (NOVN)’s Sandoz division had urged the FDA to create a pathway to start reviewing biosimilars as required by last year’s health-care law. Access to lower-cost versions of biologic

muscle in emerging markets and looking for a new product to revive the fortunes of its vaccines unit. But what really gives Novartis enduring strength is its long and successful track record at developing new drugs that can clear the bar on unmet medical needs.

YORK, Feb. 9, 2012 /PRNewswire/ -- Just weeks after winning preliminary approval of a 99 million dollar settlement on behalf of Novartis Pharmaceuticals Sales Representatives, Attorneys from Sanford Wittels & Heisler, LLP today filed a class action complaint

Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.” Email: jackfriday2011(at)hotmail.co.uk insider The term "PR" means someth

me in automatically next time Novartis's Bexsero MenB vaccine is immunogenic, but is it cost-effective? Today Alex Shimmings Please Login to read the full article. Novartis's novel meningococcal B vaccine Bexsero should slot seamlessly into routine infant

global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes us one of the most rewarding

Chief Jimenez: "I knew exactly what I was getting into." This story ran in the February 27, 2012, edition of Forbes under the headline “Anticipation.” When you ask around the drug industry who the best leader of the last two decades was, Daniel Vasella’s name

Sabine Baerlocher of Active Relocation, told swissinfo.ch. A straw poll of four multinationals in Switzerland – ABB, Nestlé, Novartis and Roche - found they recommend new arrivals learn a local language but it isn’t obligatory. “Most of the time the expatriate

property protection; competition in general; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred